Director dealing
Summary by AI BETAClose X
6 January 2026
AQSE: EDX
("EDX Medical" or the "Company")
Director dealing
CAMBRIDGE, UK: EDX Medical Group, plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that Jason Holt, chairman of the Company, purchased 150,000 ordinary shares in the Company at a price per share of 11.23 pence, followed by a further 50,000 ordinary shares in the Company at a price per share of 12.00 pence on January 5, 2026.
Taken together, a total of 200,000 shares was purchased at an average price per share of 11.42 pence.
Following these transactions, Mr Holt now owns 4,600,000 shares in the Company, representing 1.19% of the issued share capital.
The directors of the Company accept responsibility for the contents of this announcement.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Jason Holt |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Company Chairman |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
EDX Medical Group PLC |
|||
|
b)
|
LEI
|
213800BZVJZTMCZ6DJ63 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
|||
|
Identification code |
ISIN: GB00BNDMJS47 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of shares on market |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price |
Volume |
|
|
|
|
|
£0.1123 |
150,000 |
|
|
|
|
|
|
£0.1200 |
50,000 |
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
200,000 |
||||
|
|
|
||||
|
- Price |
£0.1142 |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
2026-01-02 2026-01-05 |
|||
|
f)
|
Place of the transaction
|
AQSG - Aquis Growth Market (Equity) |
|||
(1) Commission Delegated Regulation (EU) 2016/522 of 17 December 2015 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council as regards an exemption for certain third countries public bodies and central banks, the indicators of market manipulation, the disclosure thresholds, the competent authority for notifications of delays, the permission for trading during closed periods and types of notifiable managers' transactions (see page 1 of this Official Journal).
ENDS
Contacts:
|
EDX Medical Group plc |
|
|
|
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)
|
+44 (0)20 3179 5300 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856
+44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Tim Metcalfe Graham Herring |
+44 (0) 203 934 6630 |
Notes to Editors:
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 40 minutes ago AVI Global Trust
- 50 minutes ago LSL Property Services
- 53 minutes ago Bluebird Merchant Ventures (DI)
- 1 hour ago Power Probe PLC
- 1 hour ago Origin Enterprises (CDI)